Modality
Fusion Protein
MOA
PD-1i
Target
PRMT5
Pathway
Amyloid
PVGBM
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
May 2022
→ Aug 2026
Phase 1Current
NCT05618821
526 pts·GBM
2024-05→2026-08·Active
NCT03053062
765 pts·GBM
2022-05→2026-06·Not yet recruiting
1,291 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-273mo awayPh2 Data· GBM
2026-08-094mo awayPh2 Data· GBM
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2026-06-27 · 3mo away
GBM
Ph2 Data
2026-08-09 · 4mo away
GBM
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05618821 | Phase 1/2 | GBM | Active | 526 | NT-proBNP |
| NCT03053062 | Phase 1/2 | GBM | Not yet recr... | 765 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 |